🎉 M&A multiples are live!
Check it out!

Suven Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Suven Pharma and similar public comparables like Syngene International, Dishman Carbogen Amics, and Piramal Pharma.

Suven Pharma Overview

About Suven Pharma

Suven Pharmaceuticals Ltd is involved in developing and manufacturing intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company operates majorly in the Manufacturing (CRAMS) segment, which includes bulk drugs and intermediates under contract services. Its geographical segments include India, the USA, Europe, and the Rest of the World. The majority of the company's revenue comes from the Europe segment.


Founded

2018

HQ

India
Employees

1.1K+

Website

suvenpharm.com

Financials

LTM Revenue $252M

LTM EBITDA $85.0M

EV

$3.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Suven Pharma Financials

Suven Pharma has a last 12-month revenue of $252M and a last 12-month EBITDA of $85.0M.

In the most recent fiscal year, Suven Pharma achieved revenue of $120M and an EBITDA of $54.3M.

Suven Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Suven Pharma valuation multiples based on analyst estimates

Suven Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $155M $120M XXX XXX XXX
Gross Profit $85.3M $86.6M XXX XXX XXX
Gross Margin 55% 72% XXX XXX XXX
EBITDA $71.2M $54.3M XXX XXX XXX
EBITDA Margin 46% 45% XXX XXX XXX
Net Profit $52.7M $47.8M XXX XXX XXX
Net Margin 34% 40% XXX XXX XXX
Net Debt $5.9M $0.5M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Suven Pharma Stock Performance

As of April 15, 2025, Suven Pharma's stock price is INR 1150 (or $13).

Suven Pharma has current market cap of INR 293B (or $3.4B), and EV of INR 286B (or $3.3B).

See Suven Pharma trading valuation data

Suven Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$3.3B $3.4B XXX XXX XXX XXX $0.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Suven Pharma Valuation Multiples

As of April 15, 2025, Suven Pharma has market cap of $3.4B and EV of $3.3B.

Suven Pharma's trades at 13.2x LTM EV/Revenue multiple, and 39.1x LTM EBITDA.

Analysts estimate Suven Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Suven Pharma and 10K+ public comps

Suven Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $3.3B XXX XXX XXX
EV/Revenue 15.5x XXX XXX XXX
EV/EBITDA 43.8x XXX XXX XXX
P/E 65.7x XXX XXX XXX
P/E/Growth 1.5x XXX XXX XXX
EV/FCF 2411.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Suven Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Suven Pharma Valuation Multiples

Suven Pharma's NTM/LTM revenue growth is 57%

Suven Pharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $26K for the same period.

Over next 12 months, Suven Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Suven Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Suven Pharma and other 10K+ public comps

Suven Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -22% XXX XXX XXX XXX
EBITDA Margin 35% XXX XXX XXX XXX
EBITDA Growth -24% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 92% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $26K XXX XXX XXX XXX
S&M Expenses to Revenue 1% XXX XXX XXX XXX
G&A Expenses to Revenue 2% XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 22% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Suven Pharma Public Comps

See public comps and valuation multiples for Contract Research & Manufacturing comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Jubilant Pharmova XXX XXX XXX XXX XXX XXX
Biocon XXX XXX XXX XXX XXX XXX
Syngene International XXX XXX XXX XXX XXX XXX
Dishman Carbogen Amics XXX XXX XXX XXX XXX XXX
Piramal Pharma XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Suven Pharma M&A and Investment Activity

Suven Pharma acquired  XXX companies to date.

Last acquisition by Suven Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Suven Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Suven Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Suven Pharma

When was Suven Pharma founded? Suven Pharma was founded in 2018.
Where is Suven Pharma headquartered? Suven Pharma is headquartered in India.
How many employees does Suven Pharma have? As of today, Suven Pharma has 1.1K+ employees.
Is Suven Pharma publicy listed? Yes, Suven Pharma is a public company listed on BOM.
What is the stock symbol of Suven Pharma? Suven Pharma trades under 543064 ticker.
When did Suven Pharma go public? Suven Pharma went public in 2020.
Who are competitors of Suven Pharma? Similar companies to Suven Pharma include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics.
What is the current market cap of Suven Pharma? Suven Pharma's current market cap is $3.4B
What is the current revenue of Suven Pharma? Suven Pharma's last 12-month revenue is $252M.
What is the current EBITDA of Suven Pharma? Suven Pharma's last 12-month EBITDA is $85.0M.
What is the current EV/Revenue multiple of Suven Pharma? Current revenue multiple of Suven Pharma is 13.2x.
What is the current EV/EBITDA multiple of Suven Pharma? Current EBITDA multiple of Suven Pharma is 39.1x.
What is the current revenue growth of Suven Pharma? Suven Pharma revenue growth between 2023 and 2024 was -22%.
Is Suven Pharma profitable? Yes, Suven Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.